# Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea

> **NCT03925441** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 2 (actual)

## Conditions studied

- Psoriasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03925441
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-25
- **Primary completion:** 2019-08-06
- **Final completion:** 2019-08-06
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2020-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03925441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03925441, "Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03925441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*